NEWSROOM
Press Releases by Agendia
News
Press Releases
Landmark Long-Term Data from EORTCโs MINDACT Study Published in The Lancet Oncology
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ March 12, 2021 โ Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term follow up data from MINDACT, the prospective, randomized trial Read More
Data Presented at the Miami Breast Cancer Conference Show MammaPrintยฎ and BluePrintยฎ Accurately Predict Pathologic Complete Response Rate Regardless of Age
Results support use of Agendiaโs genomic tests to better tailor pre-operative treatment and timing for surgery IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from Read More
Agendia to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Agendia to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Thursday, February 04, 2021 02:00:00 PM (GMT) Agendia, Inc., a world leader in precision oncology for breast cancer, today announced Read More
Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, which will take place from Monday, January 11 through Thursday, Read More
Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 11, 2020 โ Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted Read More
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting First look at full 5-year NBRST trial outcome and survival data illustrate genomic diversity Read More
Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion
Agendia and Roche evaluate BluePrintโs stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 10, 2020 โ Agendia, Inc., a world leader in precision oncology Read More